A new standard related to the handling of hazardous drugs (HDs) with closed system drug-transfer devices (CSTDs) recently issued by the American Society of Clinical Oncology (ASCO) has rekindled a controversy underway for more than a year, with ASCO’s recommendations differing radically from those of pharmacists involved in assessment of these devices.
One of five newly published ASCO standards (J Clin Oncol 2019;37[7]:598-609), the CSTD standard states that the support for